SCHEMBL6419092

SCHEMBL6419092

Nc1nc(O)c2c(n1)CCCC2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.59
ACHE P22303 12/20 0.52
ALDH1A1 P00352 4/20 0.50
MAPK1 P28482 2/20 0.50
MAPT P10636 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
BPTF Q12830 1/20 0.50
APAF1 O14727 1/20 0.50
NSD2 O96028 1/20 0.50
TP53 P04637 1/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HRH2 P25021 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
NOS3 P29474 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4123899 0.98 KDM4E (0.57) KDM4EACHEALDH1A1MAPK1MAPT
SCHEMBL13394086 0.96 KDM4E (0.53) KDM4EACHEALDH1A1MAPK1MAPT
SCHEMBL3563842 0.77 KDM4E (0.63) KDM4EACHEALDH1A1MAPK1MAPT
SCHEMBL6457198 0.77 ACHE (0.44) KDM4EACHEALDH1A1MAPK1MAPT
SCHEMBL29466625 0.77 ACHE (0.44) KDM4EACHEALDH1A1MAPK1MAPT
SCHEMBL15831714 0.76 ACHE (0.43) KDM4EACHEALDH1A1MAPK1MAPT
SCHEMBL10513696 0.74 KDM4E (0.44) KDM4EACHEMAPK1MAPTMEN1
SCHEMBL8943915 0.74 ACHE (0.41) KDM4EACHEALDH1A1MAPK1MAPT
SCHEMBL6415610 0.74 KDM4E (0.59) KDM4EACHEALDH1A1MAPK1MAPT
SCHEMBL1617798 0.74 KDM4E (0.59) KDM4EACHEALDH1A1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951866-B2 Bicyclic pyrimidine compounds and therapeutic use thereof SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-10-04 US disclosed
EP-1110951-B1 PYRIMIDINE DERIVATIVES SUMITOMO PHARMA (JP) 2004-05-19 EP disclosed
US-20030105323-A1 Pyrimidine derivative SUMITOMO PHARMACEUTICALS COMPANY LIMITED 2003-06-05 US disclosed
US-6458798-B1 HAS AN INHIBITORY ACTIVITY OF PRODUCTION OF TH2 TYPE CYTOKINES SUCH AS IL-4, IL-5, ETC., AND IS USEFUL AS AN THERAPEUTIC AGENT FOR ALLERGIC DISEASES, AUTOIMMUNE DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATHOSUS, ETC., AND ACQUIRED SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-10-01 US disclosed
EP-1110951-A1 PYRIMIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-06-27 EP disclosed
US-5760043-A USING 2-AMINOPYRIDINE-3-OXIDE L'OREAL (FR) 1998-06-02 US disclosed
US-5610302-A TREATMENT OF DISEASES OF SCALP DERMATITIS L'OREAL (FR) 1997-03-11 US disclosed
EP-0422178-B1 PYRIMIDINE DERIVATIVES ZENECA LTD (GB) 1994-10-05 EP disclosed
US-5223505-A PYRIMIDINE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-29 US disclosed
EP-0422178-A1 PYRIMIDINE DERIVATIVES. ICI PLC (GB) 1991-04-17 EP disclosed
WO-1990012790-A1 PYRIMIDINE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105323-A1 Pyrimidine derivative IL5, IL4, IL15 KDM4E 1077/4885ACHE 4681/4885ALDH1A1 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.